RU2011100106A - Замещенные бензимидазолы для лечения нейрофиброматоза - Google Patents
Замещенные бензимидазолы для лечения нейрофиброматоза Download PDFInfo
- Publication number
- RU2011100106A RU2011100106A RU2011100106/15A RU2011100106A RU2011100106A RU 2011100106 A RU2011100106 A RU 2011100106A RU 2011100106/15 A RU2011100106/15 A RU 2011100106/15A RU 2011100106 A RU2011100106 A RU 2011100106A RU 2011100106 A RU2011100106 A RU 2011100106A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- formula
- halogen
- neurofibromatosis
- tautomer
- Prior art date
Links
- 208000009905 Neurofibromatoses Diseases 0.000 title claims abstract 14
- 201000004931 neurofibromatosis Diseases 0.000 title claims abstract 14
- 150000001556 benzimidazoles Chemical class 0.000 title 1
- 229910052736 halogen Inorganic materials 0.000 claims abstract 19
- 150000001875 compounds Chemical class 0.000 claims abstract 14
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims abstract 12
- 150000002367 halogens Chemical class 0.000 claims abstract 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 9
- 238000000034 method Methods 0.000 claims abstract 9
- 150000003839 salts Chemical class 0.000 claims abstract 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 7
- 208000013355 benign neoplasm of brain Diseases 0.000 claims abstract 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims abstract 6
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 5
- 208000009798 Craniopharyngioma Diseases 0.000 claims abstract 4
- 208000001154 Dermoid Cyst Diseases 0.000 claims abstract 4
- 206010028980 Neoplasm Diseases 0.000 claims abstract 4
- 208000003019 Neurofibromatosis 1 Diseases 0.000 claims abstract 4
- 208000024834 Neurofibromatosis type 1 Diseases 0.000 claims abstract 4
- 210000002987 choroid plexus Anatomy 0.000 claims abstract 4
- 201000002222 hemangioblastoma Diseases 0.000 claims abstract 4
- 206010027191 meningioma Diseases 0.000 claims abstract 4
- 208000002761 neurofibromatosis 2 Diseases 0.000 claims abstract 4
- 208000022032 neurofibromatosis type 2 Diseases 0.000 claims abstract 4
- 210000004560 pineal gland Anatomy 0.000 claims abstract 4
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims abstract 3
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims abstract 3
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 claims abstract 3
- 125000004414 alkyl thio group Chemical group 0.000 claims abstract 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims abstract 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 3
- 230000002265 prevention Effects 0.000 claims abstract 3
- 125000001424 substituent group Chemical group 0.000 claims abstract 3
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 claims abstract 2
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 claims abstract 2
- 208000007538 neurilemmoma Diseases 0.000 claims 3
- -1 C 1 -C 6 alkyl Chemical group 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000003154 papilloma Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6115608P | 2008-06-13 | 2008-06-13 | |
| US61/061,156 | 2008-06-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2011100106A true RU2011100106A (ru) | 2012-10-27 |
Family
ID=40956523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011100106/15A RU2011100106A (ru) | 2008-06-13 | 2009-06-11 | Замещенные бензимидазолы для лечения нейрофиброматоза |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20110092546A1 (enExample) |
| EP (1) | EP2288354A1 (enExample) |
| JP (1) | JP2011524362A (enExample) |
| KR (1) | KR20110025827A (enExample) |
| CN (1) | CN102065859B (enExample) |
| AU (1) | AU2009257487B2 (enExample) |
| BR (1) | BRPI0915106A2 (enExample) |
| CA (1) | CA2726376A1 (enExample) |
| MX (1) | MX2010013683A (enExample) |
| RU (1) | RU2011100106A (enExample) |
| TW (1) | TW201004621A (enExample) |
| WO (1) | WO2009152288A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120189633A1 (en) | 2011-01-26 | 2012-07-26 | Kolltan Pharmaceuticals, Inc. | Anti-kit antibodies and uses thereof |
| EP4063391A1 (en) | 2012-07-25 | 2022-09-28 | Celldex Therapeutics, Inc. | Anti-kit antibodies and uses thereof |
| JP6768639B2 (ja) | 2014-05-23 | 2020-10-21 | セルデックス セラピューティクス，インコーポレーテッド | 好酸球又はマスト細胞関連障害の治療 |
| KR101880015B1 (ko) | 2017-12-08 | 2018-07-19 | 아주대학교산학협력단 | 인터페론 감마를 유효성분으로 함유하는 신경섬유육종 예방 또는 치료용 조성물 |
| CA3126021A1 (en) | 2019-01-11 | 2020-07-16 | Naegis Pharmaceuticals Inc. | Leukotriene synthesis inhibitors |
| WO2022268158A1 (zh) * | 2021-06-23 | 2022-12-29 | 正大天晴药业集团股份有限公司 | 作为c-Met激酶抑制剂的化合物治疗I型神经纤维瘤病的用途 |
| US20250235458A1 (en) * | 2021-10-08 | 2025-07-24 | Universite Claude Bernard Lyon 1 | Benzimidazole derivatives for use in the treatment or prevention of a histiocytosis or a craniopharyngioma |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04009541A (es) * | 2002-03-29 | 2005-01-25 | Chiron Corp | Benzazoles sustituidos y uso de los mismos como inhibidores de cinasa raf. |
| PE20070335A1 (es) * | 2005-08-30 | 2007-04-21 | Novartis Ag | Benzimidazoles sustituidos y metodos para su preparacion |
| GB0609378D0 (en) * | 2006-05-11 | 2006-06-21 | Novartis Ag | Organic compounds |
| PE20130814A1 (es) * | 2006-08-30 | 2013-08-08 | Novartis Ag | Sales de benzimidazolil piridil eteres y formulaciones que las contienen |
| US20100074897A1 (en) * | 2006-12-01 | 2010-03-25 | University Of Utah Research Foundation | Methods and Compositions related to HIF-1 alpha |
| CA2694646C (en) * | 2007-07-30 | 2017-09-05 | Ardea Biosciences, Inc. | Combinations of mek inhibitors and raf kinase inhibitors and uses thereof |
| WO2009114703A2 (en) * | 2008-03-12 | 2009-09-17 | Fox Chase Cancer Center | Combination therapy for the treatment of cancer |
-
2009
- 2009-06-11 US US12/997,770 patent/US20110092546A1/en not_active Abandoned
- 2009-06-11 CN CN2009801221827A patent/CN102065859B/zh not_active Expired - Fee Related
- 2009-06-11 KR KR1020117000776A patent/KR20110025827A/ko not_active Withdrawn
- 2009-06-11 BR BRPI0915106A patent/BRPI0915106A2/pt not_active IP Right Cessation
- 2009-06-11 MX MX2010013683A patent/MX2010013683A/es not_active Application Discontinuation
- 2009-06-11 AU AU2009257487A patent/AU2009257487B2/en not_active Ceased
- 2009-06-11 JP JP2011513674A patent/JP2011524362A/ja not_active Withdrawn
- 2009-06-11 CA CA2726376A patent/CA2726376A1/en not_active Abandoned
- 2009-06-11 RU RU2011100106/15A patent/RU2011100106A/ru not_active Application Discontinuation
- 2009-06-11 WO PCT/US2009/046971 patent/WO2009152288A1/en not_active Ceased
- 2009-06-11 EP EP09763578A patent/EP2288354A1/en not_active Ceased
- 2009-06-12 TW TW098119822A patent/TW201004621A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN102065859A (zh) | 2011-05-18 |
| TW201004621A (en) | 2010-02-01 |
| CA2726376A1 (en) | 2009-12-17 |
| WO2009152288A1 (en) | 2009-12-17 |
| KR20110025827A (ko) | 2011-03-11 |
| CN102065859B (zh) | 2012-10-03 |
| MX2010013683A (es) | 2011-04-26 |
| EP2288354A1 (en) | 2011-03-02 |
| US20110092546A1 (en) | 2011-04-21 |
| JP2011524362A (ja) | 2011-09-01 |
| AU2009257487B2 (en) | 2013-01-31 |
| AU2009257487A1 (en) | 2009-12-17 |
| BRPI0915106A2 (pt) | 2016-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008125055A (ru) | 2-(фенил или гетероцикло)-1h-фенантро[9.10-d]имидазолы в качестве ингибиторов mpges-1 | |
| RU2011146363A (ru) | Производные n-ацил-n-фенилпиперазина, используемые (кроме того) для профилактики или лечения диабета | |
| RU2012127334A (ru) | Производные 5-замещенного хиназолинона, содержащие их композиции и способы их применения | |
| JP2020503299A5 (enExample) | ||
| NZ590268A (en) | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | |
| AR057109A1 (es) | Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis | |
| JP2011502958A5 (enExample) | ||
| PE20110062A1 (es) | N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo | |
| NZ611528A (en) | Neprilysin inhibitors | |
| RU2011127451A (ru) | ПРОИЗВОДНЫЕ ТИЕНО[3,2-c]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ РАКА | |
| RU2012116877A (ru) | Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы | |
| RU2011140869A (ru) | Пиперазиновое соединение, ингибирующее простагландин-d-синтазу | |
| RU2008120850A (ru) | Соединения и композиции в качестве ингибиторов протеинкиназ | |
| JP2011524362A5 (enExample) | ||
| RU2009131697A (ru) | Применение ингибитора trpm5 для регулирования секреции инсулина и гпп-1 | |
| JP2019529487A5 (enExample) | ||
| JP2009501745A5 (enExample) | ||
| RU2372348C2 (ru) | Производные индолилмалеимида в качестве ингибиторов ркс | |
| RU2011105059A (ru) | Применение производных пиримидиламинобензамида для лечения фиброза | |
| RU2015150287A (ru) | Новые соединения 3,4-дигидро-2н-изохинолин-1-она и 2,3-дигидроизоиндол-1-она | |
| RU2015150614A (ru) | Новые 3, 4-дигидро-2н-изохинолин-1-оны и 2, 3-дигидро-изоиндол-1-оны | |
| EA200600570A1 (ru) | Замещенные 2-карбониламино-6-пиперидинаминопиридины и замещенные 1-карбониламино-3-пиперидинаминобензолы как агонисты 5-ht | |
| EA200701780A1 (ru) | Противоопухолевое средство | |
| JP2006503857A5 (enExample) | ||
| ZA200704913B (en) | 3-[2-(3-acylamino-2-oxo-2H-pyridin-1-YL)-acetylamino]-4-oxo-pentanoic acid derivatives and their use as caspase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20140616 |